Skip to main content

Resources tagged with “atrial septal defect (ASD)”

GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects

Data from the Gore ASSURED Clinical Study demonstrated 100 percent closure success at six months

Jun 4, 2019

Gore Receives CE Mark for the GORE® CARDIOFORM ASD Occluder for the Treatment of Atrial Septal Defects in Europe

CE Mark supported by data from the Gore ASSURED Clinical Study, demonstrating 100 percent closure success

Oct 2, 2019

Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder

New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure

Sep 26, 2017

FDA Approves GORE® CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke

Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone

Apr 3, 2018

Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure

Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone

May 16, 2017